Edition:
India

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

80.90USD
20 Sep 2019
Change (% chg)

$1.50 (+1.89%)
Prev Close
$79.40
Open
$79.19
Day's High
$81.32
Day's Low
$79.19
Volume
354,959
Avg. Vol
163,417
52-wk High
$102.37
52-wk Low
$45.15

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines Announces FDA Acceptance Of New Drug Application For Avapritinib For The Treatment Of PDGFRA Exon 18 Mutant Gist And Fourth-Line Gist
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AVAPRITINIB FOR THE TREATMENT OF PDGFRA EXON 18 MUTANT GIST AND FOURTH-LINE GIST.BLUEPRINT MEDICINES CORP - FDA GRANTED PRIORITY REVIEW AND SET AN ACTION DATE OF FEBRUARY 14, 2020 UNDER PRESCRIPTION DRUG USER FEE ACT.  Full Article

Blueprint Medicines Announces European Medicines Agency Validation Of Marketing Authorization Application For Avapritinib
Friday, 19 Jul 2019 

July 18 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR AVAPRITINIB FOR THE TREATMENT OF PDGFRΑ D842V MUTANT GIST AND FOURTH-LINE GIST.BLUEPRINT MEDICINES CORP - VALIDATION OF MAA FOR AVAPRITINIB CONFIRMS THAT APPLICATION IS SUFFICIENTLY COMPLETE TO BEGIN FORMAL REVIEW PROCESS.  Full Article

Blueprint Medicines Announces Proposed Offering Of Shares
Thursday, 28 Mar 2019 

March 27 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.BLUEPRINT MEDICINES CORP - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION IN SHARES OF COMMON STOCK.  Full Article

Blueprint Medicines Announces Accelerated Regulatory Submission Plans
Thursday, 28 Mar 2019 

March 27 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES ACCELERATED REGULATORY SUBMISSION PLANS AND RECENT CLINICAL PROGRESS.BLUEPRINT MEDICINES CORP - BLU-667: PLAN TO SUBMIT NDA FOR PREVIOUSLY TREATED RET-FUSION NON-SMALL CELL LUNG CANCER IN Q1 2020.BLUEPRINT MEDICINES CORP - AVAPRITINIB: PLAN TO SUBMIT MAA FOR PDGFRΑ D842V MUTANT GIST AND FOURTH-LINE GIST IN Q3 2019.BLUEPRINT MEDICINES CORP - BLU-782: PLAN TO INITIATE PHASE 2A TRIAL IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA IN Q4 2019.BLUEPRINT MEDICINES CORP - PLAN NDA FOR ADVANCED SYSTEMIC MASTOCYTOSIS IN Q1 2020 FOR AVAPRITINIB.  Full Article

Blueprint Medicines Reports Q4 Loss Per Share Of $1.83
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.83.Q4 EARNINGS PER SHARE ESTIMATE $-1.76 -- REFINITIV IBES DATA.BLUEPRINT MEDICINES - AS OF DEC 31, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $494.0 MILLION VERSUS $673.4 MILLION AS OF DEC 31, 2017.QUARTERLY COLLABORATION REVENUE $1.0 MILLION VERSUS $1.6 MILLION.BLUEPRINT MEDICINES - TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO H2 2020.  Full Article

Blueprint Medicines Reports Q2 Loss Per Share $0.62
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.62.Q2 EARNINGS PER SHARE VIEW $-1.32 -- THOMSON REUTERS I/B/E/S.BLUEPRINT MEDICINES - EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS SUFFICIENT TO ENABLE IT TO FUND OPERATING EXPENSES & CAPEX INTO H2 2020.AS OF JUNE 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $616.7 MILLION, VERSUS $673.4 MILLION AS OF DECEMBER 31, 2017.  Full Article

Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.70 MILLION COMMON SHARES PRICED AT $81.00PER SHARE.  Full Article

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.BLUEPRINT MEDICINES CORP SAYS IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275.0 MILLION IN SHARES OF ITS COMMON STOCK.BLUEPRINT MEDICINES-EXPECTS TO USE PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR AVAPRITINIB IN GASTROINTESTINAL STROMAL TUMORS,SYSTEMIC MASTOCYTOSIS.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-554 IN HEPATOCELLULAR CARCINOMA.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-667 IN RET-DRIVEN CANCERS.  Full Article

Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes.Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​.Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​.  Full Article

Blueprint Medicines Q3 loss per share $0.96
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​.  Full Article